INTERCEPT SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess

INTERCEPT SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick &
Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead
Plaintiff Deadline in Class Action Lawsuit Against Intercept Pharmaceuticals,
Inc. -- ICPT

NEW ORLEANS, Feb. 21, 2014 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF")
and KSF partner, the former Attorney General of Louisiana, Charles C. Foti,
Jr., remind investors that they have until April 22, 2014 to file lead
plaintiff applications in a securities class action lawsuit against Intercept
Pharmaceuticals, Inc. (Nasdaq:ICPT), if they purchased the Company's
securities during the period between January 9, 2014 and January 10, 2014,
inclusive (the "Class Period"). This action is pending in the United States
District Court for the Southern District of New York.

What You May Do

If you purchased shares of Intercept and would like to discuss your legal
rights and how this case might affect you and your right to recover for your
economic loss, you may, without obligation or cost to you, call toll-free at
1-877-515-1850, or email KSF Managing Partner Lewis Kahn
(lewis.kahn@ksfcounsel.com) or KSF Partner Melinda Nicholson
(melinda.nicholson@ksfcounsel.com). If you wish to serve as a lead plaintiff
in this class action, you must petition the Court by April 22, 2014.

About the Lawsuit

Intercept and certain of its executives are charged with issuing a series of
materially false and misleading statements during the Class Period, violating
federal securities laws.

On January 9 and 10, 2014, Intercept announced that its Phase 2 trial of its
primary drug compound obeticholic acid had been stopped early based on an
interim analysis that showed that the efficacy endpoint of the trial had been
met.

Then, on Friday, January 10, 2014, after the markets closed, the National
Institutes of Health issued a written statement revealing that, while the
efficacy primary endpoint in the study had already been met, participants in
the study who received the drug suffered disproportionate levels of lipid
abnormalities. On this news, Intercept's stock price plummeted.

About Kahn Swick & Foti, LLC

To learn more about KSF, whose partners include the Former Louisiana Attorney
General, Charles C. Foti, Jr., and other lawyers with significant experience
litigating complex securities class actions nationwide on behalf of both
institutional and individual shareholders, you may visit www.ksfcounsel.com.

CONTACT: Kahn Swick & Foti, LLC
         Lewis Kahn, Managing Partner
         lewis.kahn@ksfcounsel.com
         Melinda Nicholson, Partner
         melinda.nicholson@ksfcounsel.com
         1-877-515-1850
         206 Covington St.
         Madisonville, LA 70447
 
Press spacebar to pause and continue. Press esc to stop.